Concepedia

Author

Olwen Hahn

University of Chicago

Also Known As

Berry, Donald A., Hahn, Olwen M., Moynahan, Mary Ellen, O. Hahn, O. M. Hahn, O. M. hahn, O., Hahn, O.M. Hahn, Olwen Hahn, Olwen M Hahn

140

Publications

5.2K

Citations

31

H-Index

50

Concepts

All Affiliations

University of ChicagoMemorial Sloan Kettering Cancer CenterDana-Farber Cancer InstituteMayo ClinicDuke University
OH

About

Olwen Hahn is an author at University of Chicago specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

21

1.1K

2

Health Sciences

6

6

267

3

Education

3

3

95

4

Public Health

2

2

104

5

Biostatistics

1

1

18

Olwen Hahn

×

48

Publications

4.8K

Citations

29

H-Index

YearCitations

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

William M. Sikov, Donald A. Berry, Charles M. Perou,

Journal of Clinical Oncology

2014

1K

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

Toni K. Choueiri, Susan Halabi, Ben L. Sanford,

Journal of Clinical Oncology

2017

707

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber,

Annals of Oncology

2022

404

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Toni K. Choueiri, Colin Hessel, Susan Halabi,

European Journal of Cancer

2018

392

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma

Olwen Hahn, Cheng Yang, Milica Medved,

Journal of Clinical Oncology

2008

227

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

Michael Gnant, Amylou C. Dueck, Sophie Frantal,

Journal of Clinical Oncology

2021

220

Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database

Daniel S. Peiffer, Fangyuan Zhao, Nan Chen,

JAMA Oncology

2023

126

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Maura N. Dickler, William T. Barry, Constance Cirrincione,

Journal of Clinical Oncology

2016

125

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde,

New England Journal of Medicine

2024

125

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

Aranzazu Fernández-Martínez, Ian E. Krop, David W. Hillman,

Journal of Clinical Oncology

2020

122

Page 1